Vimarsana
Biggest News Aggregation in the World

Page 3 - Full Analysis Set News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Full Analysis Set. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Full Analysis Set Today - Breaking & Trending Today

vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury - Vimarsana News

vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical...

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury - Vimarsana News

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/PRNewswire/ -- vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,...

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury - Vimarsana News

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

- Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early - Significantly less aggressive critical care with maintained renal function in young adults -

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury - Vimarsana News

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/PRNewswire/ -- vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,...

F. Hoffmann-La Roche Ltd: Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% - Vimarsana News

F. Hoffmann-La Roche Ltd: Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

F. Hoffmann-La Roche Ltd: Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% Placebo Risk reduction 13 1.2 4 copies/mL) 14 0.4 * Individuals without any COVID-19 symptoms who lived in the same household as an individual who tested positive to SARS-CoV-2 within the prior four days . Based on the seronegative modified Full Analysis Set population, which includes all randomized subjects without evidence of current or prior SARS-CoV-2 infection (i.e., a negative RT...